Sandoz will appeal District Court of New Jersey ruling in biosimilar Erelzi U.S. patent case
HOLZKIRCHEN, Germany – Sandoz, a Novartis division and a global leader in biosimilars, today announced that the United States District Court of New Jersey ruled against Sandoz in patent litigation concerning the Sandoz biosimilar, Erelzi (etanercept-szzs) for reference medicine Enbrel (etanercept).